☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search category
Search here
Search here
Subscribe Now
Merck
Merck Commences P-III Study of MK-1084 Plus Keytruda as a Treatment of Metastatic Non-Small Cell Lung Cancer
April 5, 2024
Merck and Daiichi Sankyo Commences P-II/III (REJOICE-Ovarian01) Study of Raludotatug Deruxtecan for Treating Ovarian Cancer
April 4, 2024
Merck’s Keytruda Combined with Chemotherapy Receives EC’s Approval for the Treatment of Non-Small Cell Lung Cancer
March 28, 2024
Merck’s Winrevair (sotatercept-csrk) Receives the US FDA’s Approval for the Treatment of Pulmonary Arterial Hypertension (PAH)
March 27, 2024
Merck Reports Data from the P-III (KEYLYNK-006) Study of Keytruda for Treatment of Metastatic Non-squamous NSCLC
March 21, 2024
Merck Highlights Results from Various P-III Trials of V116 Vaccine for Pneumococcal Diseases at ISPPD-13 2024
March 20, 2024
Load more...
Back to Home